This study is exploring cemiplimab, an experimental drug, for treating skin cancers known as Cutaneous Squamous Cell Carcinoma (CSCC) and Basal Cell Carcinoma (BCC). The focus is to understand how safe cemiplimab is and how well people tolerate it. The study also examines side effects, effects on tumors, and how much drug is in the blood over time.

Key Points:

• The study lasts for 12 weeks with weekly doses.
• Participants must have CSCC or BCC that meets specific conditions.
• Those with certain other health conditions, prior treatments, or recent COVID-19 vaccinations are not eligible.

Eligibility includes a history of resectable (removable by surgery) CSCC or BCC, and a performance status indicating good overall health. Exclusions include recent significant autoimmune disease, prior treatments blocking certain pathways, history of organ transplants, or recent COVID-19 vaccination. Always consult with a healthcare provider before deciding to participate in any study.